30
2021-04
Kintor Has Expanded Its Geographical Presence to Zhuhai
Zhuhai, China, Apr.30, 2021--Kintor Pharmaceutical Limited announced today that the company has expanded geographical presence to Zhuhai, Guangdong Province (“Zhuhai office”).
25
2021-04
Suzhou, China, April.25, 2021 — Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the phase III clinical trial of proxalutamide for the treatment of male patients with mild or moderate COVID-19 symptoms in the United States has completed the first patient enrollment and dosing.
16
2021-04
SUZHOU, China, Apr 16, 2021--Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced today the clinical trial of Pyrilutamide as a treatment for the acne vulgaris has completed the first batch of patients enrolment and successfully dosed in China.
15
2021-04
Suzhou, Apr.15, 2021--Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that it has received approval from the National Medical Products Administration to begin clinical trials for GT20029 (gel/tincture) for the treatment of acne and androgenetic alopecia.
12
2021-04
Suzhou, Apr.12, 2021--Kintor Pharmaceutical Limited (stock code 9939.HK, “Kintor Pharmaceutical” or the “Company”), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced a strategic partnership with Hainan Visum Pharmaceutical Limited (“Visum”) to expand proxalutamide manufacturing.
09
2021-04
Kintor Announces Presentation of Preclinical Data at AACR 2021
Suzhou, Apr.9, 2021--Kintor Pharmaceutical Limited , a clinical-stage biotechnology company developing small molecule and biological therapeutics, today announced two poster presentations of preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2021, including proxalutamide(GT0918) to treat COVID-19 and a c-Myc inhibitor to treat blood cancer.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn